In this interview we discuss the goals of the Community Oncology Alliance, highlights from their annual meeting, and the challenge of transitioning cancer care to the hospital setting.
Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life
In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms.
This article will outline key information needed and practical ways that clinicians can integrate fertility preservation discussions and guidelines into their day-to-day practice.
Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets—PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor
Here we review drugs that target the EGFR and VEGF pathways, focusing on patient selection, drug toxicities, and how to choose agents for first-line therapy.
A 46-year-old woman had a routine screening mammogram that showed new calcifications in the posterior left breast. A diagnostic mammogram showed several small punctate calcifications, and a 6-month interval follow-up was recommended.
The understanding of the relationship between genetic variation and an individual patient’s response to radiation therapy has gained significant ground over the past several years. Genetic markers have been identified that could ultimately serve as the foundation for predictive models in clinical practice, and that hold the potential to revolutionize the delivery of precision medicine in oncology.
As specific candidate genes become more well established and gene expression assays gain sophistication, the value in clinical outcomes prediction and treatment selection is expected to transform the practice of radiation oncology.
Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets—PART 2: Approaches Beyond First-Line Therapy, and Novel Biologic Agents Under Investigation
Here we review the evidence for use of biologic agents in the second-line setting and beyond. We also discuss off-label indications for biologics in selected patient populations, as well as biologics currently under development.